Probuphine, a buprenorphine subdermal implant formulation for adults with opioid dependence has been given a green light by an FDA Advisory Committee (Panel). The Panel cited a favorable benefit-risk profile and an unmet need. According to Titan Pharmaceuticals Inc., the FDA Panel voted 10 to 4 in favor, with one abstention...